Skip to main content
profile image
Selected Works of Walter J. Urba, MD, PhD
Article
A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer.
Journal for ImmunoTherapy of Cancer (2015)
  • Walter Urba, Earle A. Chiles Research Institute, Portland, OR, USA
  • Bartosz Chmielowski, University of California, Los Angeles
  • Deryk Loo, MacroGenics, San Francisco, CA, USA
  • Jan Baughman, MacroGenics, San Francisco, CA, USA
  • Francine Chen, MacroGenics, San Francisco, CA, USA
  • Paul Moore, MacroGenics, Rockville, MD, USA
  • Ezio Bonvini, MacroGenics, Rockville, MD, USA
  • James Vasselli, MacroGenics, Rockville, MD, USA
  • Jon Wigginton, MacroGenics, Rockville, MD, USA
  • Naiyer Rizvi, Columbia University Medical Center
Link
Disciplines
Publication Date
January 1, 2015
DOI
10.1186/2051-1426-3-S2-P176
Citation Information
Walter Urba, Bartosz Chmielowski, Deryk Loo, Jan Baughman, et al.. "A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer." Journal for ImmunoTherapy of Cancer Vol. 3 Iss. 2 (2015) p. 176
Available at: http://works.bepress.com/walter-urba/251/